Feed ICR-PA
Summary
17 / 100 · Bulios Score
Valuation 0Growth 0Profitability 0Quality 12Debt 58Stability 52
What speaks for it
- The price moves less than the market (beta 0.23).
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 8.3% a year over the last 3 years.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (AUD)
20202021202220232024
Diluted EPS (AUD)
20202021202220232024
Revenue fell by 8.3% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Cash and short-term investments $91.3M
Debt $363.5M
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, at risk20212022202320242025
- Yield
- 8.77%
You receive $1.69 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.